Summit Therapeutics's total assets for Q4 2024 were $435.56M, a decrease of -13.38% from the previous quarter. SMMT total liabilities were $46.81M for the fiscal quarter, a -27.91% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.